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Abstract
Introduction: Microcirculation dysfunction is a typical feature of systemic sclerosis (SSc) and represents the earliest
abnormality of primary myocardial involvement. We assessed coronary microcirculation status by combining two
functional tests in SSc patients and estimating its impact on disease outcome.
Methods: Forty-one SSc patients, asymptomatic for coronary artery disease, were tested for coronary flow velocity
reserve (CFR) by transthoracic-echo-Doppler with adenosine infusion (A-TTE) and for left ventricular wall motion
abnormalities (WMA) by dobutamine stress echocardiography (DSE). Myocardial multi-detector computed
tomography (MDCT) enabled the presence of epicardial stenosis, which could interfere with the accuracy of the
tests, to be excluded. Patient survival rate was assessed over a 6.7- ± 3.5-year follow-up.
Results: Nineteen out of 41 (46%) SSc patients had a reduced CFR (≤2.5) and in 16/41 (39%) a WMA was observed
during DSE. Furthermore, 13/41 (32%) patients showed pathological CFR and WMA. An inverse correlation between
wall motion score index (WMSI) during DSE and CFR value (r = -0.57, P <0.0001) was observed; in addition, CFR
was significantly reduced (2.21 ± 0.38) in patients with WMA as compared to those without (2.94 ± 0.60) (P
<0.0001). In 12 patients with abnormal DSE, MDCT was used to exclude macrovasculopathy. During a 6.7- ± 3.5-
year follow-up seven patients with abnormal coronary functional tests died of disease-related causes, compared to
only one patient with normal tests.
Conclusions: A-TTE and DSE tests are useful tools to detect non-invasively pre-clinical microcirculation
abnormalities in SSc patients; moreover, abnormal CFR and WMA might be related to a worse disease outcome
suggesting a prognostic value of these tests, similar to other myocardial diseases.
Introduction
Until two decades ago, clinical evidence of cardiac invol-
vement in systemic sclerosis (SSc) was considered an
infrequent event and it mainly resulted from autopsy stu-
dies. In particular, overt manifestations of ischemic heart
disease were considered rare, cardiac failure was observed
in about 10% of cases, and pericarditis in 15% [1-4].
Conversely, post mortem investigations demonstrated
myocardial lesions secondary to SSc in more than 50% of
cases [2].
The discrepancy between the high prevalence of sclero-
derma heart involvement (SHI) at autopsy studies and of
its lower detection by in vivo studies might be due to the
low sensitivity or to the scarce applicability of the diagnos-
tic tools utilized [5]. On the other hand, when SHI
becomes clinically evident, it assumes a deeply negative
prognostic significance, with a mortality rate above 70% at
five years [6]. Detailed reviews of the clinical studies con-
cerning SHI have recently been published [7-9]. However,
data on the prognostic impact of sub-clinical myocardial
involvement as detected by more sensitive tests in SSc
patients are presently lacking.
The pathogenesis of SHI is still debated; the most fre-
quent pathological features of SSc in the myocardium
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are focal fibrosis (in more than 50% of cases) and con-
traction band necrosis (CBN) (in 77% of patients) [2].
Follansbee et al. [10] found a high prevalence of CBN in
SSc patients with SHI, probably related to an inter-
mittent vascular spasm of the coronary arteries with
episodes of ischemia-reperfusion [2].
The small coronary vessels show a reduced patency or
obliteration due to intimal proliferation, fibrinoid necrosis,
fibrosis and intravascular coagulation [11]. The microvas-
cular structural and functional abnormalities seem to lead
to the increased fibroblast activity and disseminated tissue
fibrosis [12], which may progress to a clinical pattern of
restrictive cardiomyopathy [13].
The consequences of such anatomical damage and
functional disorder were reported in subsequent studies.
Kahan et al. [14] first demonstrated the impairment of
coronary vasodilator reserve using coronary catheterism,
later confirmed by non-invasive adenosine transthoracic
echocardiography (A-TTE) by other groups [15,16]. In
addition, myocardial scintigraphy enabled several authors
to observe reversible myocardial perfusion defects,
induced either by exposure to the cold or by physical
exercise [17-19].
Dobutamine stress echocardiography (DSE) enables
evaluation of the dynamics of left ventricular wall
motion, which correlate to perfusion and oxygen supply,
during chronotropic and inotropic pharmacological
stress. This test is a well- established diagnostic and
prognostic tool that has widespread applicability because
of its clinical accuracy and cost effectiveness [20].
Some authors demonstrated that the simultaneous eva-
luation of coronary flow velocity reserve (CFR) and left
ventricular wall motion (LVWM) by dipyridamole stress
echocardiography increases the diagnostic power of each
test to detect coronary macro- and micro-vascular invol-
vement [21,22].
In order to increase the accuracy of these two methods,
the presence of epicardial artery stenosis should be
excluded, and in patients with pre-clinical SHI, where an
invasive procedure is not ethically applicable, myocardial
multi-detector computed tomography (MDCT) might be
preferable in order to avoid cardiac catheterization [23].
On this basis, the presence of early myocardial func-
tional changes in SSc patients asymptomatic for coronary
artery disease (CAD) was investigated by combined
A-TTE and DSE, integrating them, when applicable, with
MDCT, and the impact of such abnormalities on mortality
was determined.
Materials and methods
The initial population comprised 97 SSc patients, who ful-
filled the American College of Rheumatology classification
criteria [24], followed from September 2000 to June 2006
at our Department. Exclusion criteria were: 1) technically
poor acoustic window precluding satisfactory imaging of
the left ventricle (for 2-D echo) or of left anterior descend-
ing coronary artery (LAD) flow by Color Doppler (for CFR
assessment) (16 patients), 2) a right ventricular systolic
pressure >40 mmHg by echocardiography (12 patients), 3)
hemodynamic instability (2 patients), valvular disease
(5 patients), CAD (3 patients), unstable angina (1 patient),
life-threatening arrhythmias (1 patient), severe lung and/or
pulmonary vascular disease (6 patients), 4) asthma or
severe chronic obstructive pulmonary disease (6 patients),
and 5) inability or refusal to give informed consent
(6 patients). None of them showed symptoms or signs of
congestive heart failure, CAD or arrhythmia. Treatment
with calcium channel blockers and prostanoids was
suspended 48 hours and 4 weeks before functional tests,
respectively. All the studied subjects were requested to
avoid xanthine-containing food and drinks for ≥24 hours
before evaluation. The study was approved by the ethics
committee of Cagliari University Hospital (Italy), and writ-
ten informed consent was obtained from all participants.
The final study population consisted of 41 patients; among
them, 30 represented the initial cohort who underwent
DSE in our previous study [25]. Hematochemical and
serological tests, chest X-ray, lung function tests and CT
examination, ECG, basal M-mode and two-dimensional
echocardiography were carried out on all subjects.
Follow-up
Following initial cardiac evaluations, all patients were
followed up for a mean period of 6.7 ± 3.5 years.
Adenosine Transthoracic Echochardiography (A-TTE)
In all patients, CFR was assessed by A-TTE as previously
described [15]. Briefly, CFR was evaluated in the LAD with
transthoracic Color Doppler during adenosine infusion.
The pulsed wave Doppler examination of blood flow velo-
city was recorded in the LAD at rest and after maximum
vasodilation by adenosine infusion (140 μg/kg/min for
three to five minutes). When the Doppler signal was
suboptimal, Levovist® (Schering AG, Berlin, Germany), a
suspension of monosaccharide (galactose) microparticles
in sterile water, was infused at a concentration of 300
mg/ml, at a rate of 0.5 to 1 ml/min. The CFR value was
expressed as the ratio of peak diastolic velocity during
hyperaemia to peak diastolic velocity at rest (baseline).
CFR values ≤2.5 were considered impaired, as previously
reported [15].
Dobutamine stress echocardiography protocol
All patients underwent DSE. After baseline data had been
acquired, dobutamine was infused, beginning at a dose of
5 mcg/Kg/min, and increasing every three minutes to a
maximum dose of 40 mcg/Kg/min. Echocardiograms
were recorded at baseline, low dose, peak dose and five
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minutes into recovery. When necessary, atropine (up to 1
mg) was given intravenously at the higher dose levels to
augment heart rate response. Assessment was performed
by two experienced investigators who had no knowledge
of CFR data. The following scoring system was used for
regional wall motion: normal = 1; hypokinetic = 2;
akinetic = 3; diskinetic = 4. For segmental analysis of left
ventriculum (LV) function, a 16-segment model was used
as suggested by the American Society of Echocardiogra-
phy [26]. A Wall Motion Score Index (WMSI) was cal-
culated at baseline and at peak stress as the sum of
scores divided by the number of analyzed segments.
End points for dobutamine infusion were: achievement
of target heart rate (85% of the maximal heart rate pre-
dicted for age), maximal dose of dobutamine and atro-
pine, extensive new wall-motion abnormalities, >2 mm
ST-segment depression in two or more ECG leads,
chest pain, significant arrhythmias, severe hypertension
(blood pressure >220 mmHg) or hypotension (a fall in
systolic blood pressure >30 mmHg). ECG and blood
pressure were monitored continuously and recorded at
each stage.
Coronary multi-detector computed tomography
The indication to perform MDCT was based on the pre-
sence of WMA at the DSE test. MDCT was carried out
using a multi-detector computerized tomograph with
eight lines of detectors and a rotation time of 500 msec on
360° and with a slice depth of 1.3 mm (Light Speed Ultra,
General Electric Medical Systems, Milwaukee, WI, USA).
Retrospective gating was used. A total of 120 ml of non-
ionic contrast medium was injected at 4 ml/sec. Images
were processed as appropriate on a SUN-80 ULTRA
workstation (Sun Microsystems, Palo Alto, CA, USA). The
entire examination lasted from 20 to 30 minutes. Image
evaluation was carried out by an expert radiologist aware
of patients’ diagnoses.
Statistical analysis
All data are presented as mean ± SD. Comparisons were
made with an independent t-test or a non-parametric test
(Mann-Whitney, chi-square or Fisher’s exact test), when
appropriate. Relationships between CFR, WMSI and pro-
tocol variables were evaluated with the simple linear corre-
lation coefficient r (determination coefficient r2), P-values
less than or equal to 0.05 were considered significant.
Kaplan-Meier method survival curves were used to
summarize the follow-up experience in these patients.
The differences in survival curves were tested with a
log-rank statistic. The association of selected variables
with outcome was assessed with the Cox proportional
hazard model using univariate and stepwise multivariate
procedures. A significance of 0.05 was required for a
variable to be included in the multivariate model,
whereas 0.1 was the exclusion cut-off value. Hazard
ratios with the corresponding 95% confidence intervals
were estimated. Data management and analysis were
performed using MedCalc software (version. 12.2.1;
Mariakerker, Belgium).
Results
Forty-one consecutive SSc patients (33 female, 8 male;
mean age 54.1 y, range 28 to 73) with mean disease
duration of 7.5 y (range 1 to 22 y) were included in the
study. Fifteen out of the 41 SSc patients were affected
by dcSSc subtype and 26 by lcSSc form, according to
the LeRoy et al. classification [27]. Demographic, clinical
and laboratory data of patients are reported in Table 1.
Echocardiographic and functional cardiac parameters
determined in SSc patients studied are listed in Tables 2
and 3. Both cardiac stress tests were well tolerated and
no cardiac adverse events occurred during examinations.
The median interval time between A-TTE and DSE was
1.5 weeks.
Nineteen out of 41 (46%) patients with SSc showed
reduced CFR (≤2.5) and in 16/41 (39%) SSc patients
WMA (hypokinesia), which was absent on baseline rest
examination, was observed during dobutamine infusion
(Figure 1). Thirteen out of 41 patients (32%) showed
both CFR and DSE test impaired; these combined abnor-
mal findings were more frequent in the subgroup with
dcSSc (8/15; 53%) than in the lcSSc subset (5/26; 19%)
(P <0.04), while they were irrespective of age, disease
duration, presence of anti Scl-70 or anti-centromere anti-
body, esophageal and lung involvement, digital ulcers,
high cholesterol serum levels and blood pressure.
WMA during DSE were limited to one segment in
10 patients, to two segments in 5 patients and to three
segments in 1 patient. In seven patients with abnormal
DSE, WMA were localized in the LAD coronary artery
area, in three patients in both the LAD and right coronary
artery area, whereas in three patients wall motion abnorm-
alities were only in the right coronary artery area and in
three patients in circumflex coronary area.
An inverse correlation between CFR and WMSI (r =
-0.57, P <0.0001) was observed (Figure 2). Moreover, CFR
was significantly reduced in patients with induced WMA
during DSE (2.21 ± 0.38 vs 2.94 ± 0.60, P = <0.0001); in
detail, 13/16 patients (81%) with WMA during DSE also
had impaired CFR and only 3 had normal CFR, while
among patients without WMA only 6 (24%) showed pat-
hologically reduced CFR and 19 had normal values
(P <0.0001).
The presence of epicardial artery stenosis, which might
affect the two functional tests’ results, could be excluded
by MDCT in 12 patients with WMA, as the examination
was declined by 3 patients and 1 died before MDCT was
performed.
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Survival analysis
Following cardiac examination, patients were followed
for 6.7 ± 3.5 years and 9/41 patients (20%) died. Death
was related to lung malignancy in two patients and to
progression of scleroderma in seven (renal crisis in one
patient, sudden death in three, pulmonary arterial hyper-
tension in two and acute respiratory failure in one).
It is worth noting that all seven patients who died as a
result of disease progression had impaired CFR and six
had WMA at the beginning of follow-up; moreover, they
all had the dcSSc form. In summary, six deaths occurred
among the 13 patients with combined pathological tests
for coronary microvascular function compared to one
death among the remaining 28 without occurrence of
combined abnormalities at the functional tests (P <0.01).
Univariate analysis showed that dcSSc (P = 0.01, HR
8.17, 95% CI 1.82 to 36.63), impaired CFR (P = 0.006),
WMA (P = 0.02, HR 8.05, 95% CI 1.80 to 36.02), and the
combination of CFR impairment and WMA (P = 0.002,
HR 12.74, 95% CI 2.60 to 62.36) were predictors of unfa-
vorable prognosis. Multivariate analysis confirmed that
simultaneous CFR impairment and WMA were indepen-
dent risk factors for mortality (P = 0.003). Kaplan-Meier
analysis showed 10-year survival rates of 96.5% and 59%,
respectively, in patients with simultaneous CFR >2.5
and no WMA versus those with CFR ≤2.5 and WMA
(P <0.002) (Figure 3).
Discussion
Early detection of SHI is related to the sensitivity of the
diagnostic tools used. The different methods reported in
available literature evaluated either functional disorders
of coronary microcirculation or functional myocardial
abnormalities. The first include evaluation of CFR with
invasive and non-invasive tests [14,15] and evaluation
Table 1 Demographic and clinical features of systemic sclerosis patients
dcSSc lcSSc
Demographic and clinical features Data Range Data range P-value
Number of patients 15 26
Age (yrs; mean; SD) 53 ± 13.1 28 to 71 52 ± 9.3 39 to 73 NS
M/F ratio 2/13 6/20 NS
Disease duration (yrs; mean; SD) 8 ± 3.3 2 to 15 8.5 ± 5.8 1 to 21 NS
Clinical manifestation
Raynaud phoenomenon 15 (100%) 23 (88%) NS
Teleangectasias 10 (66%) 9 (35%) NS
Lung involvement 13 (87%) 14 (54%) NS
Oesophagus involvement 14 (93%) 9 (35%) 0.001
Trophic ulcers 10 (66%) 8 (31%) 0.06
Calcinosis 0 5 (19%) NS
Serological findings
Anti-Scl-70 12 (80%) 10 (38%) 0.02
Anti-Centromere 0 6 (23%) NS
Risk factor for CAD
Hypertension 4 (27%) 9 (35%) NS
Diabetes 2 (13%) 2 (7%) NS
Hypercholesterolemia 6 (40%) 4 (15%) NS
Treatment
D-Penicillamine 3 (19%) 5 (19%) NS
Cyclophosphamide 8 (50%) 0 0.0004
Cyclosporine 3 (19%) 3 (11%) NS
Iloprost 13 (87%) 9 (35%) 0.003
Steroids 6 (37%) 2 (7%) 0.004
Calcium-blockers 3 (19%) 1 (3%) NS
ACE-inhibitors 3 (19%) 1 (3%) NS
Angiotensin II receptor blocker 2 (13%) 1 (3%) NS
Table 2 Echocardiographic and hemodynamic parameters
of systemic sclerosis patients
Cardiac parameters Mean ± SD
LV diastolic diameter (mm) 44.9 ± 6.3
LV EF (Simpson Biplano) (%) 66.0 ± 5.4
Thickness of the interventricular septum (mm) 9.5 ± 1.3
E/A 1.0 ± 0.3
E/A, early/late diastolic velocity ratio; EF, ejection fraction; LV, left ventricle
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of myocardial perfusion with SPECT and MRI [17,18,
28-30]. The second include evaluation of systolic or dia-
stolic dysfunction by Doppler echocardiography [31-35]
and tissue-Doppler echocardiography [36].
To our knowledge, this is the first report where two
non-invasive methods, one exploring coronary microvas-
cular function (A-TTE test) and the other perfusion- and
metabolism-dependent contractility (DSE test), have been
combined and complementarily applied in SSc to detect
pre-clinical cardiac involvement; furthermore, we sug-
gested that CFR and DSE impairment might have an
impact on the prognosis of such patients.
Our findings can be summarized as follows. First,
impaired myocardial microcirculation has been con-
firmed in SSc patients in the absence of any CAD related
symptoms and signs as revealed by non-invasive methods
Table 3 Cardiac parameters during dobutamine stress echocardiography (mean values ± standard deviation)
Pts with normal DSE (n = 25) Pts with abnormal DSE (n = 16) P-value
Heart rate(beats/min)
Baseline 75.3 ± 17.3 79.3 ± 8 ns
Max DSE 138 ± 12.5 129.7 ± 17.2 ns
Sistolic BP (mmHg)
Baseline 120 ± 18.7 117.5 ± 14.4 ns
Max DSE 136.1 ± 22.9 131.6 ± 20.3 ns
BP, blood pressure; DSE, dobutamine stress echocardiography test; Max, maximal; ns, not significant
Figure 1 Doppler echocardiography image of a SSc patient with WMA and impaired CFR. Doppler echocardiography image of a patient
with wall motion abnormalities (hypokinesia of apical segments) during Dobutamine Stress Echocardiography (upper panel) and abnormal
Coronary Flow Reserve (lower pannel).
Vacca et al. Arthritis Research & Therapy 2013, 15:R8
http://arthritis-research.com/content/15/1/R8
Page 5 of 9
whose diagnostic concordance is good [21,22]. Second,
the combined CFR impairment and WMA occurrence
seem to identify a subset of SSc patients at higher risk for
a worse outcome and might provide the potential to clo-
sely monitor and counteract myocardial damage with
more aggressive treatments, whereas patients with nor-
mal CFR and negative stress tests have showed a favour-
able outcome (no deaths in this group during follow-up).
Our study demonstrated the complementary use of
CFR and WMA in SSc. CFR impairment, already
reported in a smaller series of SSc patients [15], in the
absence of major epicardial coronary arteries stenosis
[23], could explain the segmental kinetic abnormalities
during pharmacologic stimulus. In fact, the genesis of the
LVWMA induced by dobutamine infusion is likely to be
linked to the relative ischemia secondary to inotropic and
chronotropic stimuli in patients with impaired CFR. As
already demonstrated in other series of patients at high
risk of CAD, the combined result of low CFR and abnor-
mal LVWM should address stenosis of epicardial arteries
[22], but as is reported in the literature, macrovascular
disease is considered in SSc as frequent as expected in
the general population [37-39]. An inverse correlation
between WMSI and CFR was found in our SSc patients,
similar to other pathological conditions where microvas-
cular dysfunction is present, such as after reperfusion in
acute myocardial infarction [40] and dilated cardiomyo-
pathy [41]. During dobutamine infusion, an increase in
oxygen consumption occurs; thus if concomitant micro-
vascular dysfunction with reduced CFR is present, we can
hypothesize that the mismatch between oxygen demand
and supply could induce regional LVWMA. On the other
hand, the incomplete overlap between patients with
abnormal DSE and with impaired CFR may be explained
by the fact that CFR is a more sensitive parameter of
microvascular impairment and could be an early marker
of endothelial dysfunction, which does not normally
induce regional WMA.
Another interesting finding in our series is the absence
of WMA abnormalities at baseline examination, suggest-
ing that they are neither directly referable to the patchy
areas of fibrosis reported in the literature [2,42] nor to
atherosclerotic CAD, but rather to the expression of a
functional defect, preceding the anatomical lesion, as seen
during stress [25]. Moreover, WMA did not correspond to
any epicardial coronary artery distribution, as demon-
strated by cardiac MDCT; therefore, they are highly sug-
gestive of microvascular abnormalities [23,39].
The CFR impairment and DSE pattern abnormalities
observed in our SSc patients seem to be a direct expres-
sion of SHI, and it is conceivable that these alterations
might have an unfavorable impact on the disease outcome.
In the current study, we found that the presence of
abnormal CFR and/or WMA was related to a worse
outcome. In fact, the high mortality observed in the
group with both tests abnormal suggests that coronary
Figure 2 Inverse correlation between CFR and WMSI in examined SSc patients. Relationship between coronary flow reserve (CFR) and wall
motion score index (WMSI) in systemic sclerosis patients. WMSI = difference between rest and peak WMSI (0 to 1 minute after the end of peak dose).
Vacca et al. Arthritis Research & Therapy 2013, 15:R8
http://arthritis-research.com/content/15/1/R8
Page 6 of 9
microcirculation dysfunction, although clinically silent,
needs a more specific and earlier therapeutic approach.
Although only three of the patients with abnormal myo-
cardial tests died of cardiac related causes, we cannot
exclude that impaired CFR and WMA could be one of
the early expressions of microcirculation involvement
which might influence prognosis, independently of the
cause of death. In this context, the evidence of microcir-
culation abnormalities may be a manifestation of present
or future severe heart disease. It has been described that
reduced CFR, in the absence of CAD, negatively influ-
ences prognosis in different myocardial diseases
[41,43,44]; looking at these studies, CFR might become a
new therapeutic target in the near future [45].
Our data also highlighted a significantly elevated fre-
quency of both CFR and WMA in patients with dcSSc in
comparison to those with lcSSc. Since the mean disease
duration appears to be similar in patients with the two
cutaneous disease subsets, this difference might be the
expression of a more rapid and/or severe progression of
myocardial involvement in dsSSc, in agreement with the
different timing of development of visceral lesions in the
two SSc subsets.
Evaluation of coronary microcirculation with A-TTE
and DSE appears to be complementary to the standard
echo-color-Doppler technique currently utilized in routine
assessment of cardiac abnormalities detectable in SSc
patients (pulmonary hypertension, ventricular hypertro-
phy, valve lesions, alterations of diastolic or systolic func-
tion); moreover, when compared to other stress imaging
techniques with comparable prognostic value, such as
myocardial perfusion scintigraphy, stress echocardiogra-
phy has clear advantages: lower cost, higher specificity (no
need for coronary angiography) and lack of radiation
exposure. Doppler echocardiography CFR may be a suita-
ble tool in this clinical condition, while the potential role
of CT scanning has yet to be established, and its costs and
limited availability do not allow its routine use in clinical
practice [43,44,46].
Our data have some limitations as this study was carried
out in a series of patients from a single clinical center;
therefore, further studies by other investigators in a larger
Figure 3 Kaplan-Meier survival curves in patients stratified according to normal CFR/no WMA and abnormal CFR/WMA. Kaplan-Meier
survival curves in patients stratified according to normal coronary flow reserve (CFR >2.5) and no wall motion abnormalities (WMA) versus
abnormal CFR (CFR ≤2.5) and WMA at Doppler echocardiography. The worst survival is observed in patients with abnormal CFR.
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cohort are required to confirm our results; the examina-
tions are dependent on image quality and need an expert
reader. The high radiation exposure with MDCT although
lower than catheterization, is another aspect which should
be taken into account [47]. The relatively small number of
deaths can reduce the statistical power on the mortality
data.
Further studies should also target the potential use of
A-TTE and DSE in evaluating the benefits of pharmaco-
logical treatment on small coronary vessel disease in
SSc. An example of that is the recent evaluation of
the effects of a non-conventional short-term treatment
(l-propionylcarnitine) on the coronary microvasculature
in SSc patients with impaired CFR [48].
Conclusions
In summary, we confirmed pre-clinical coronary microcir-
culation impairment in a large series of SSc patients,
asymptomatic for CAD, by two complementary non-inva-
sive tests. During a 10-year follow-up, we observed that
patients with coronary microcirculation abnormalities had
a worse prognosis.
An extension of the follow-up of the patients evalu-
ated in this study is in progress in order to further
assess the power of A-TTE and DSE in providing an
early prospective index of silent SHI progression and a
reliable prognostic score in SSc.
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